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Background: Cancer–testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues,
may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression
of CT antigens in breast cancer.
Patients and methods: A total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER)
positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by
immunohistochemistry.
Results: A significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared
with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%)
ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with
two (4%) ER-positive tumors.
Conclusions: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers.
Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be
useful for patients with this phenotype of breast cancer.
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introduction
Cancer–testis (CT) antigens are encoded by a group of genes
predominantly expressed in human germline cells. They are
down-regulated in somatic adult tissues but may become
aberrantly reexpressed in various malignancies [1]. To date,
almost a 100 genes and gene families encoding CT antigens
have been identified. CT antigens mapping to chromosome X
are referred to as CT-X antigens and distinguished from non-X
CT antigens located on other chromosomes [1–3]. The
expression of CT-X antigens varies greatly between tumor
types, being most frequent in melanomas, bladder, lung,
ovarian and hepatocellular carcinomas and uncommon in
renal, colon and hematological malignancies [4]. CT-X antigen
expression is associated with a poorer outcome and is more
prevalent in higher grade and advanced stage tumors [5–9].
Intensive research into their possible use in therapeutic vaccines
is ongoing and several clinical vaccine trials employing CT-X
antigens, in particular antigens of the MAGE-A family and
NY-ESO-1, in patients with lung, ovarian cancers and
melanoma are ongoing or have been completed [10–16].
However, few studies have explored the presence of CT
antigens in breast cancer rendering contradictory results
[17–20]. Interestingly, recent analysis in a limited number of
patients indicated a higher incidence of CT-X antigen
expression in triple-negative (TN) primary breast cancer [21].
Since TN breast cancer carries a worse clinical prognosis,
presence of CT antigens would offer additional
immunotherapeutic options. Consequently, in the present
study, we analyzed a larger series of breast cancers for
the presence of CT antigen. In order to elucidate the potential
increased expression of CT antigens, we compared a larger




The study is based on the breast database of the European Institute of
Oncology, Milan, Italy, and contains medical history, concurrent diseases,
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biological features for all consecutive breast cancer patients who underwent
surgery from January 1997 to December 2001. From this series of patients,
a total of 100 invasive breast cancer cases—50 hormone-receptor-positive
and 50 TN cases—were selected and corresponding paraffin blocks were
retrieved from the archives of the Division of Pathology at the European
Institute of Oncology. Tumor classification was done according to the
World Health Organization Histological Classification of Breast Tumors,
modified by Rosen and Obermann [22]. Tumor grade was assessed
according to Elston and Ellis [23].
immunohistochemistry
Estrogen receptor (ER) and progesterone receptor (PgR) status as well
as Ki-67-labeling index were assessed as previously reported [24, 25].
HER2 immunohistochemical (IHC) expression was evaluated using
a 1 : 400 dilution of a polyclonal antiserum (Dako, Glostrup, Denmark).
All tumors with equivocal (IHC 2+) results for HER2 were tested for gene
amplification by FISH (Vysis PathVysion; Abbott, Chicago, IL). ER and/or
PgR positivity was defined as tumors showing ‡50% expression in the
neoplastic cells. TN tumors were characterized by a lack of
immunoreactivity for ER as well as PgR and as negative by both IHC and
FISH for HER2. All ER- and PgR-positive cases were centrally testes for
HER2 expression. HER2 IHC expression was evaluated using
a 1 : 400 dilution of a polyclonal antiserum (Dako). IHC expression was
scored by two pathologists as follows: 0 (no staining or faint membrane
staining), 1+ (faint membrane staining in >10% of tumor cells, incomplete
membrane staining), 2+ (weak to moderate membrane staining in >10%
of tumor cells) and 3+ (intense circumferential membrane staining in >10%
of tumor cells). For this analysis, HER2 scores of 0 and 1+ were
considered negative.
NY-ESO-1 and MAGE-A expression was assessed on whole tissue
sections by IHC. For the analysis of NY-ESO-1, monoclonal antibody E978
(1 : 200) was used [26]. For the detection of MAGE-A antigens, an
antibody cocktail consisting of monoclonal antibodies 6C1, MA454,
M3H67 and 57B was employed (1 : 40) [27–29]. Tissue specimens were
dewaxed and heated in an antigen retrieval solution [EDTA buffer (1 mM,
pH 8.0)] for 15 min (NY-ESO-1) and 30 min (MAGE-A), respectively,
at 99C. The sections were then incubated with the primary antibodies
overnight at 4C. The EnVision Mouse (Dako) was used as a secondary
detection system and diaminobenzidine tetrahydrochloride served as
a chromogen. Sections of normal human testis with intact
spermiogenesis were used as positive controls for both NY-ESO-1 and
MAGE-A. The MAGE-A cocktail was tested for the first time on
human samples.
scoring
NY-ESO-1 and MAGE-A IHC staining results were scored using
a semiquantitative scoring system as previously described [30]. This
method takes into account both the percentage of immunoreactive tumor
cells and the staining intensity. The percentage of positive cells is then
multiplied by the intensity of staining (1+, 2+ or 3+), and the final score
ranges from 0 (no staining) to 300 (diffuse and strong immunostaining
of all the tumor cells).
statistical methods
Fisher’s exact test was used to test for difference of antigen expression
between ER-positive responsive and TN breast cancers [31]. Different
cut-offs of expression (i.e. 1+, 2+ and 3+)—as described by Domfeh et al.
[30]—were considered to define the presence of antigen expression.
Armitage’s test for trend was also used, considering the degree of
expression on an ordinal scale. All reported \P values were two sided.
results
From January 1997 to December 2001, a total of 5910 pT1-3
pN0-3 M0 patients with breast cancer were referred to the
institute for clinical care and therapy and their data were
included in the database. From this population, a total of
50 consecutive female patients with highly ER-positive and
HER2-negative breast cancers (ER) and 50 patients with TN
breast cancer were identified. The baseline pathological
characteristics of ER and TN breast tumors are listed in Table 1.
As expected, certain histopathological features differed among
ER and TN breast cancer patients. All ER-positive patients were
also HER2 negative at a central revision (see Table 1).
All samples were examined for MAGE-A and NY-ESO-1
expression by IHC (Figures 1 and 2). An heterogeneous
staining pattern was present within specific tumor samples,
ranging from 1+ to 3+. In Figure 2, the visual scale shows
intensity (red for 3+, green for 2+ and blue for 1+) and
percentage of staining for each of the tumor samples. Table 2
shows the overexpression of the two antigens in ER and TN
tumors, according to different cut-offs. MAGE-A
overexpression (score ‡2+) was detected in 13 (26%) TN
cancers but only in 5 (10%) ER tumors (P = 0.07). NY-ESO-1
overexpression (score ‡2+) was documented in nine (18%) TN
tumors but only in two (4%) ER lesions (P = 0.05).
We reviewed absolute number of positive cases, irrespective
of intensity and/or extent of antigen expression. We observed
16 of 50 (32%) MAGE-A-positive TN cases. On the other hand,
only 9 of 50 (18%) in the ER group were positive for MAGE-A.
When considering intensity and/or extent of immunostaining,
Table 1. Pathological characteristics of TN and ER- and PgR-positive
breast cancer
ER and PgR positive TN P value
N N % %
All samples 50 100 50 100
Histology
Ductal 49 98 41 82 0.02
Others 1 2 9 18
Gradea
1 8 16 1 2 0.03
2–3 41 82 48 96
pT
1 40 80 32 64 0.11
2–3 10 20 18 36
pN
0 26 52 35 70 0.10
1–3 24 48 15 30
Ki-67
<20% 28 56 5 10 <0.001
‡20% 22 44 45 90
HER2/neu
Negative 40 80 50 100 0.0012
1+ 10 20 0 0
aThe sum does not add up to the total because of two missing values.
TN, triple negative; ER, estrogen receptor; PgR, progesterone receptor;
pT, pathological T; pN, pathological N.
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there is more striking difference between hormone responsive
and TN cases.
When evaluating the dominant intensity pattern of
immunoreactivity, hormone-receptor-positive cases show more
cases with predominant 1+ (blue) intensity [4 of 9 (44%) for
MAGE-A and 9 of 11 (82%) for NY-ESO-1] than the TN cases
[3 of 16 (19%) for MAGE-A and 2 of 11 (18%) for NY-ESO-1].
Consequently, 2+ and/or 3+ (green/red) intensity of
immunostaining is present for the TN cases in >81% for
MAGE-A and 82% NY-ESO-1, while for the ER cases, the
numbers are 55% and 18%, respectively (Figure 1). If this is
analyzed for all 50 cases of each group, MAGE-A expression
Figure 1. MAGE-A and NY-ESO-1 expression by immunohistochemistry in human breast cancer in comparison with negative samples.
Figure 2. MAGE-A and NY-ESO-1 expression reported as intensity and percentage of stained cells in estrogen receptor- and progesterone receptor-positive
and triple-negative breast cancer patients.
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with an intensity score ‡2+ is detected in 13 of 50 (26%) TN
cancers but only in 5 of 50 (10%) ER-/PgR-positive tumors
(P = 0.07). Similarly, NY-ESO-1 expression with an intensity
score ‡2+ is documented in 9 of 50 (18%) TN tumors but only
in 2 (4%) hormone-receptor-positive lesions (P = 0.05).
When analyzing the extent of tumor staining irrespective of
the intensity score, there is a more homogeneous expression of
CT antigens in the TN cases compared with the hormone-
receptor-positive cases. The latter displayed immunostaining
in >25% of the tumor in 3 of 9 (33%) MAGE-A-positive cases
and in 0 of 11 NY-ESO-1-positive cases. On the contrary,
TN cases show antigen expression in >25% of the tumor in 7 of
16 (56%) MAGE-A-positive cases and 7 of 11 (67%) of NY-
ESO-1-positive cases (Figure 1 and 2). Taken together, the
number and extent of staining are higher for the TN cases for
the MAGE-A antigens and the expression is more
homogeneous. While for NY-ESO-1 expression there is no
difference in the absolute number between TN and hormone-
receptor-positive cases, TN cases show a more homogeneous
NY-ESO-1 expression and a higher intensity.
A combined analysis of CT-X antigen expression showed that
MAGE-A and/or NY-ESO-1 were overexpressed (score ‡2+)
more frequently in TN (34%) than in ER tumors (14%)
(P = 0.03).
Overall, no association was found between pathological
features of disease and MAGE-A and NY-ESO-1 overexpression
(score ‡2+), except for the KI-67-labeling index and MAGE-A
expression (Table 3).
discussion
Breast cancer is well recognized as a heterogeneous disease not
only from a morphological and structural standpoint but also
in its diverse functional features revealed through analysis of its
genetic signatures and other indices detectable through IHC
[32–37].
While such heterogeneity poses clinical problems, it also
offers opportunities to develop therapies making use of such
properties, as exemplified by the success of ER-directed
therapies.
TN breast cancer represents a group of tumors, which are
difficult to treat. TN cancers have been identified by gene array
analysis revealing a higher expression of clusters of
proliferation-related genes [32]. This is illustrated by a higher
Ki-67-labeling index expression in TN tumors versus
endocrine-responsive cancers [38]. Our cohort of patients
showed a similar elevated Ki-67 labeling in the TN cases.
TN tumors frequently express molecules that may drive these
proliferative processes, such as epidermal growth factor
receptor (EGFR) and vascular-related growth factors [39].
However, disappointing clinical responses to agents targeting
EGFR have been reported [40]. On the other hand, in vitro
chemosensitivity studies have shown that cells lacking BRCA1,
such as TN breast cancer cells, may be sensitive to drugs that
cause double-strand breaks in DNA [41], such as alkylating
agents. Recently, biological agents such as poly(ADP-ribose)
polymerase inhibitors (PARP inhibitors) have been studied
[42].
The early identification of features associated with response
or resistance to primary therapy is important in the
development of the most effective multimodal approaches and
identifying cohorts of patients most likely to benefit from
chemotherapy. Features predictive of response and outcome
include steroid hormone receptor expression. Pathological
complete remission (pCR) rate are significantly higher
following neoadjuvant chemotherapy for patients with TN
tumors compared with the hormone-receptor-positive cohort
[43]. Regardless of the higher likelihood of pCR for patients
with TN disease, the 5-year disease-free survival is significantly
worse for this cohort compared with the ER-positive cohort in
several studies [43]. Importantly, patients with ER-positive
residual tumors fare remarkably better than patients with
ER-negative tumors not achieving a pCR [43].
Table 2. MAGE-A and NY-ESO-1 expression in TN and ER- and
PgR-positive breast cancer
Antigen Expression ER positive TN P valuea
N % N %
MAGE-A ‡1+ 4 8 3 6
‡2+ 2 4 7 14
3+ 3 6 6 12
P trend: 0.07
Scoreb 12 (5, 270) 30 (3, 240) 0.09
NY-ESO-1 ‡1+ 9 18 2 4
‡2+ 2 4 1 2
3+ 0 0 8 16
P trend: 0.07
Scoreb 5 (1, 35) 114 (1, 285) 0.71
aWilcoxon rank sums test, comparing score distributions among
ER-positive and TN tumors, including those with no expression.
bMedian (min, max): computed in patients with expression ‡1+.
TN, triple negative; ER, estrogen receptor; PgR, progesterone receptor.
Table 3. MAGE-A and NY-ESO-1 expression (score ‡2+) and
pathological features of the breast cancers
MAGE-A ‡2 positive NY-ESO-1 ‡2 positive
% P value % P value
All samples 18 11
Histotype
Ductal 17 1.00 10 0.30
Others 20 20
Grade
1 0 0.20 0 0.59
2–3 20 11
pT
1 18 1.00 12 1.00
2–3 18 7
pN
0 16 0.60 11 1.00
1–3 21 10
Ki-67
<20% 3 0.006 9 1.00
‡20% 25 12
pT, pathological T; pN, pathological N.
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In recent years, CT antigens have emerged as new therapeutic
options for the treatment of cancer. They have been identified
in a wide variety of malignant tumors but in normal adult
tissues, CT antigens are solely present in testicular germ cells.
Due to the lack of major histocompatibility complex molecules,
male germ cells are not subjected to any potential T-cell
response and no associated side-effects have been observed in
any of the previous clinical trials employing CT antigens
[10–16]. Though a wide variety of tumors have been studied,
knowledge about presence of CT antigens on a protein level in
breast cancer is comparably limited and contradictory. In one
study of ductal carcinomas, NY-ESO-1 and/or MAGE-A
antigens were found in up to 50% and 90%, respectively [18],
while others found a much low incidence [17, 19, 20]. A more
recent study suggested an elevated expression of CT antigens in
the recently identified subtype of TN breast carcinomas [21].
However, this study was focused on messenger RNA expression
and IHC data were restricted to tissue microarray (TMA)
tissues. Our present analysis employed full sections in order to
adequately address issues such heterogeneity and intensity of
antigen expression. The previous TMA analysis did not evaluate
extent of staining and intensity, as it was done in the present
study. We show that the incidence of MAGE-A and NY-ESO-1
expression for the common hormone-receptor-positive ductal
breast is 20% for both antigens. This is below the incidence,
which has been reported in other tumors, such as melanoma
and lung cancer [5, 6]. Nevertheless, it is higher than in
previous other studies in breast cancer [17–19]. Most
interestingly is the altered expression of MAGE-A and
NY-ESO-1 in TN breast cancer of our series. There is
a disparate change of incidence for both antigens. While
MAGE-A shows a higher incidence in TN cases, in NY-ESO-1,
the number of positive cases does not change. However, the
most significant finding of our study is the increase of antigen
intensity and the extent of tumor staining. For both MAGE-A
and NY-ESO-1, there is an increased intensity and homogeneity
in antigen expression. In hormone-receptor-positive cases, the
expression of both antigens was predominantly present in
a limited fashion mostly involving <25% of the tumor.
Moreover, this expression showed a rather low intensity. In
TN breast cancer of our series, there was not only a more
homogeneous antigen expression involving larger areas of the
tumor but expression was also more intense. Expression
homogeneity and intensity have not been properly addressed in
previous analyses of breast cancer, some of which were based
on TMA slides [21]. TMA analysis is limited as to the
informative value regarding extent of antigen expression.
The fact that MAGE-A and NY-ESO-1 expression is
increased in TN breast cancer is of potential clinical relevance
specifically in the adjuvant setting of treatment. It is our current
thinking that patients with TN breast cancer and minimal
residual disease after preoperative chemotherapy are the ideal
setting to test the efficacy of a vaccination strategy. To date,
vaccines for breast cancer have been mainly used in end-stage
disease. Several clinical studies have been completed with
vaccines against antigens, such as MUC1, CEA, HER2 and the
carbohydrate antigens with varying results [44]. However,
immunotherapy might be most effective when patients have
only minimal residual disease after initial treatment. CT-X
antigens offer a novel opportunity for fostering vaccine
development and therapy. Vaccines including members of the
MAGE-A and NY-ESO-1 families are currently being tested in
clinical trials for patients with melanoma and lung cancer,
where such antigens are frequently expressed [10–16]. Our
study demonstrates MAGE-A and NY-ESO-1 antigen
expression in a group of patients for which therapeutic options
are limited. Analysis of MAGE-A and NY-ESO-1 antigen
expression in breast cancer patients after surgery may allow
identification of patients who are potential candidates for
adjuvant therapeutic vaccines.
In conclusion, MAGE-A and NY-ESO-1 may be of
therapeutic value as a vaccine-based treatment in TN breast
cancers.
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